Endothelial permeability in vitro and in vivo: Protective actions of ANP and omapatrilat in experimental atherosclerosis

Peptides

Volumn 48, Issue , 2013, Pages 21-26

  Ichiki, Tomoko ^a   Izumi, Ririko ^a   Cataliotti, Alessandro ^a   Larsen, Amy M ^a   Sandberg, Sharon M ^a   Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Angiotensin converting enzyme inhibitor; Atherosclerosis; Atrial natriuretic peptides; Endothelium; Neprilysin inhibitor

Indexed keywords

ALBUMIN; ATRIAL NATRIURETIC FACTOR; EVANS BLUE; IODINE 125; OMAPATRILAT; PLACEBO; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; ATHEROGENESIS; ATHEROMA; ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; CELL MEMBRANE PERMEABILITY; CHOLESTEROL DIET; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; VASODILATATION;

ORYCTOLAGUS CUNICULUS;

ACE; ACE INHIBITION; ACEI; ANG; ANGIOTENSIN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN CONVERTING ENZYME INHIBITOR; ANP; ATHEROSCLEROSIS; ATRIAL NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC PEPTIDES; B-TYPE NATRIURETIC PEPTIDE.; BNP; CGMP; CYCLIC GUANOSINE MONOPHOSPHATE; EC; ECP; ENDOTHELIAL CELL; ENDOTHELIAL CELL PERMEABILITY; ENDOTHELIUM; GC-A; GUANYLYL CYCLASE-A RECEPTOR; HAECS; HDL-C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN AORTIC ENDOTHELIAL CELLS; LDL-C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAP; MEAN ARTERIAL PRESSURE; NEP; NEP INHIBITION; NEPI; NEPRILYSIN; NEPRILYSIN INHIBITOR; NITRIC OXIDE; NO; OMA; OMAPATRILAT; VASCULAR SMOOTH MUSCLE CELLS; VSMCS;

ANGIOTENSINS; ANIMALS; AORTA; ATHEROSCLEROSIS; ATRIAL NATRIURETIC FACTOR; DIET, HIGH-FAT; ENDOTHELIAL CELLS; HUMANS; NEPRILYSIN; ORGAN CULTURE TECHNIQUES; PERMEABILITY; PYRIDINES; RABBITS; THIAZEPINES; VASODILATION;

EID: 84886931379     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2013.07.020     Document Type: Article

References (33)

1. Alexander DM, Williams LM, Gatt JM, Dobson-Stone C, Kuan SA, Todd EG, et al. The contribution of apolipoprotein E alleles on cognitive performance and dynamic neural activity over six decades. Biological Psychology 2007;75:229-38. (Pubitemid 46915557)
2. Barbato E, Bartunek J, Mangiacapra F, Sciarretta S, Stanzione R, Delrue L, et al. Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease. Journal of the American College of Cardiology 2012;59: 1763-70.
3. Baron DA, Lofton CE, Newman WH, Currie MG. Atriopeptin inhibition of thrombin-mediated changes in the morphology and permeability of endothelial monolayers. Proceedings of the National Academy of Sciences of the United States of America 1989;86:3394-8. (Pubitemid 19129618)
4. Buchan KW, Martin W. Modulation of barrier function of bovine aortic and pulmonary artery endothelial cells: dissociation from cytosolic calcium content. British Journal of Pharmacology 1992;107:932-8.
5. Burnett Jr JC, Kao PC, Hu DC, Heser DW, Heublein D, Granger JP, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986;231:1145-7. (Pubitemid 16016312)
6. Cannone V, Boerrigter G, Cataliotti A, Costello-Boerrigter LC, Olson TM, McKie PM, et al. A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. Journal of the American College of Cardiology 2011;58:629-36.
7. Chen W, Gassner B, Borner S, Nikolaev VO, Schlegel N, Waschke J, et al. Atrial natriuretic peptide enhances microvascular albumin permeability by the caveolae-mediated transcellular pathway. Cardiovascular Research 2012;93:141-51.
8. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sciences 1981;28:89-94. (Pubitemid 11184926)
9. Graf K, Koehne P, Grafe M, Zhang M, Auch-Schwelk W, Fleck E. Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cells. Hypertension 1995;26:230-5.
10. Haneda M, Kikkawa R, Maeda S, Togawa M, Koya D, Horide N, et al. Dual mechanism of angiotensin II inhibits ANP-induced mesangial cGMP accumulation. Kidney International 1991;40:188-94.
11. Hegde LG, Yu C, Renner T, Thibodeaux H, Armstrong SR, Park T, et al. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. Journal of Cardiovascular Pharmacology 2011;57:495-504.
12. Kangawa K, Fukuda A, Minamino N, Matsuo H. Purification and complete amino acid sequence of beta-rat atrial natriuretic polypeptide (beta-rANP) of 5,000 daltons. Biochemical and Biophysical Research Communications 1984;119:933-40. (Pubitemid 14132804)
13. Kiemer AK, Weber NC, Furst R, Bildner N, Kulhanek-Heinze S, Vollmar AM. Inhibition of p38 MAPK activation via induction of MKP-1: atrial natriuretic peptide reduces TNF-alpha-induced actin polymerization and endothelial permeability. Circulation Research 2002;90:874-81. (Pubitemid 34633879)
14. Kikuta K, Yasue H, Yoshimura M, Morita E, Sumida H, Kato H, et al. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. American Heart Journal 1996;132:101-7. (Pubitemid 26243698)
15. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs Enalapril (OCTAVE) trial. American Journal of Hypertension 2004;17:103-11. (Pubitemid 38125125)
16. Levy Z, Dvir A, Shaish A, Trestman S, Cohen H, Levkovietz H, et al. Omapatrilat, an angiotensin-converting enzyme and neutral endopeptidase inhibitor, attenuates early atherosclerosis in diabetic and in nondiabetic low-density lipoprotein receptor-deficient mice. International Journal of Experimental Diabesity Research 2003;4:59-64. (Pubitemid 37038674)
17. Melo LG, Veress AT, Ackermann U, Sonnenberg H. Chronic regulation of arterial blood pressure by ANP: role of endogenous vasoactive endothelial factors. American Journal of Physiology 1998;275:H1826-33.
18. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nature Genetics 2009;41:348-53.
19. O'Donnell ME, Owen NE. Role of cyclic GMP in atrial natriuretic factor stimulation of Na+,K+,Cl? cotransport in vascular smooth muscle cells. The Journal of Biological Chemistry 1986;261:15461-6. (Pubitemid 17208767)
20. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:920-6. (Pubitemid 34925324)
21. Sakamoto T, Nakashima Y, Sueishi K. The effect of thrombin on actin filament and vinculin of corneal endothelial cells. Investigative Ophthalmology & Visual Science 1993;34:438-46. (Pubitemid 23072880)
22. Schirger JA, Grantham JA, Kullo IJ, Jougasaki M, Wennberg PW, Chen HH, et al. Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition. Journal of the American College of Cardiology 2000;35:796-801. (Pubitemid 30170255)
23. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387-95.
24. Steiner AL, Parker CW, Kipnis DM. Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides. Journal of Biological Chemistry 1972;247:1106-13.
25. Supaporn T, Sandberg SM, Borgeson DD, Heublein DM, Luchner A, Wei CM, et al. Blunted cGMP response to agonists and enhanced glomerular cyclic 3,5 β-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney International 1996;50:1718-25. (Pubitemid 26364281)
26. Surapisitchat J, Jeon KI, Yan C, Beavo JA. Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3. Circulation Research 2007;101:811-8. (Pubitemid 350287196)
27. Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW. Harrison DG, and Medford RM. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the reninangiotensin system and atherosclerosis. Circulation 1999;100:1223-9. (Pubitemid 29426599)
28. van Nieuw Amerongen GP, Vermeer MA, Negre-Aminou P, Lankelma J, Emeis JJ, van Hinsbergh VW. Simvastatin improves disturbed endothelial barrier function. Circulation 2000;102:2803-9.
29. Vouret-Craviari V, Boquet P, Pouyssegur J, Van Obberghen-Schilling E. Regulation of the actin cytoskeleton by thrombin in human endothelial cells: role of Rho proteins in endothelial barrier function. Molecular Biology of the Cell 1998;9:2639-53. (Pubitemid 28425899)
30. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nature Reviews Immunology 2008;8:802-15.
31. Weckler N, Leitzbach D, Kalinowski L, Malinski T, Busch AE, Linz W. Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits. Journal of the Renin- Angiotensin-Aldosterone System 2003;4:191-6. (Pubitemid 37407168)
32. Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001;103:448-54. (Pubitemid 32105987)
33. Winquist RJ, Faison EP, Waldman SA, Schwartz K, Murad F, Rapoport RM. Atrial natriuretic factor elicits an endothelium-independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle. Proceedings of the National Academy of Sciences of the United States of America 1984;81:7661-4. (Pubitemid 15196244)